

e-ISN 2723-7494

Volume 52 Nomor 1 (2025)

JURNAL ILMU BEDAH INDONESIA

Diterbitkan oleh:

Ikatan Ahli Bedah Indonesia

TITLE PROSTATE-SPECIFIC ANTIGEN (PSA) SCREENING FOR EARLY DETECTION OF PROSTATE CANCER: AN EVIDENCE-BASED ANALYSIS

¹Ilham Saptia Nugraha, ²Agung Trisnanto

¹General Practitioner, ²Department of Surgery, Ungaran Regional Hospital, Ungaran, Indonesia

Background: Prostate-specific antigen (PSA) screening has transformed the early detection of prostate cancer, yet its widespread implementation remains controversial due to concerns over overdiagnosis, overtreatment, and questionable mortality benefit. **Objective:** To evaluate the contemporary evidence regarding the benefits and harms of PSA-based screening, synthesizing findings from major clinical trials, cost-effectiveness analyses, and international guidelines to inform individualized screening strategies. **Methods:** An evidence-based analysis using data from pivotal trials such as the ERSPC and PLCO, along with recent meta-analyses, biomarker advancements, MRI-based protocols, and national screening guidelines from the USPSTF, EAU, NCCN, and others. **Results:** PSA screening may reduce prostate cancer-specific mortality, particularly in men aged 55–69 years. It facilitates early detection, enhances access to curative therapies, and promotes broader health engagement. However, it carries significant risks, including overdiagnosis of indolent tumors, overtreatment-related morbidity, false positives, psychological distress, and economic burden. Mortality outcomes across studies remain inconsistent, prompting a shift toward personalized, risk-adapted screening guided by age, comorbidities, family history, biomarkers (e.g., PHI, 4Kscore), and multiparametric MRI. **Conclusion:** PSA screening should not be universally applied but rather employed through shared decision-making and individualized risk assessment. Advances in imaging and molecular diagnostics can enhance specificity, minimize harm, and improve screening value. Continued research is warranted to optimize outcomes and inform equitable screening policies, particularly in resource-limited settings.

Keywords: PSA screening; Prostate cancer; Early detection; Screening guidelines

INTRODUCTION

Prostate cancer is the second most frequently diagnosed malignancy and the fifth leading cause of cancer-related death among men worldwide, with an estimated 1.4 million new cases and 375,000 deaths reported in 2020 alone⁽¹⁾. The global burden of prostate cancer is expected to rise significantly due to increased life expectancy, widespread adoption of prostate cancer awareness programs, and expanding access to diagnostic tools such as prostate-specific antigen (PSA) testing⁽¹⁾.

PSA is a serine protease produced by epithelial cells of the prostate gland, and its concentration in the serum can be elevated in men with prostate cancer, benign prostatic hyperplasia, prostatitis, or even after certain physical activities such as cycling or ejaculation^(2,3). Since its introduction in the late 1980s, PSA testing has revolutionized the landscape of prostate cancer diagnosis by enabling earlier detection of clinically localized tumors, which may be amenable to curative intervention⁽⁴⁾.

However, the use of PSA as a population-wide screening tool has been the subject of intense debate for more than two decades. Critics argue that PSA screening leads to significant overdiagnosis of indolent prostate cancers that would not have caused symptoms or death during a man's

lifetime and consequently increases the risk of overtreatment, which can result in considerable side effects such as urinary incontinence, erectile dysfunction, and psychological distress⁽⁵⁾.

While randomized controlled trials such as the European Randomized Study of Screening for Prostate Cancer (ERSPC)⁽⁶⁾ have demonstrated a reduction in prostate cancer mortality with PSA screening, other large-scale trials, such as the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial in the United States⁽⁶⁾, did not find a statistically significant mortality benefit, partly due to contamination of the control group.

In light of conflicting evidence, recent clinical guidelines increasingly emphasize personalized screening strategies that incorporate patient age, life expectancy, comorbidities, family history, and individual values. Shared decision-making between clinicians and patients is now regarded as the cornerstone of ethically sound prostate cancer screening practices⁽⁷⁾.

This literature review aims to explore the contemporary evidence on the benefits and harms of PSA-based prostate cancer screening, highlighting the ongoing controversy and discussing the evolving recommendations from international guidelines.

DISCUSSIONS

Theoretical Basis and Mechanism of PSA

Prostate-specific antigen (PSA) is a 33-kDa glycoprotein enzyme produced almost exclusively by the epithelial cells of the prostate gland. It functions primarily as a serine protease that liquefies seminal fluid, facilitating sperm motility. Under physiological conditions, PSA is present in the blood in low concentrations, mostly bound to protease inhibitors such as alpha-1-antichymotrypsin (ACT) and alpha-2-macroglobulin, with a smaller fraction existing in a free (unbound) form⁽⁸⁾.

Elevated serum PSA levels have long been associated with prostate cancer due to disruption of the normal prostatic architecture, which facilitates the leakage of PSA into the circulation. However, PSA is not cancer-specific. Its levels may also increase in various benign and non-neoplastic conditions, including benign prostatic hyperplasia (BPH), acute or chronic prostatitis, urinary tract infection, recent ejaculation, urethral instrumentation, or digital rectal examination^(2,3).

This lack of specificity significantly limits the utility of PSA as a stand-alone diagnostic marker. It has been estimated that approximately 65%–75% of men with elevated PSA levels (>4.0 ng/mL) who undergo prostate biopsy do not have prostate cancer⁽⁹⁾. Moreover, PSA levels can fluctuate due to inter-individual biological variability and technical factors related to assay performance, time of blood draw, or prostate manipulation⁽¹⁰⁾.

To improve diagnostic accuracy, several refinements in PSA measurement have been proposed⁽¹⁰⁾. These include:

- **PSA density (PSAD):** PSA level divided by prostate volume, used to distinguish BPH-related elevation.
- **PSA velocity (PSAV):** The rate of PSA increases over time, which may reflect cancer progression.
- **Free-to-total PSA ratio (fPSA/tPSA):** Lower ratios are more likely to indicate malignancy.

Despite these adjunct measures, the inherent biological variability of PSA and its overlap between benign and malignant states continues to challenge its effectiveness as a screening tool. Thus, PSA remains a useful but imperfect biomarker, best interpreted in the context of other clinical, radiologic, and laboratory data.

Benefits of PSA Screening: Pro Arguments

Early Detection of Clinically Localized Prostate Cancer

One of the primary advantages of PSA screening is its ability to detect prostate cancer at an early, asymptomatic, and potentially curable stage. The landmark European Randomized Study of Screening for Prostate Cancer (ERSPC)⁽⁶⁾, which enrolled over 162,000 men across eight countries, demonstrated a 20% relative reduction in prostate

cancer-specific mortality after a median follow-up of 13 years among those who underwent PSA screening compared to controls⁽⁶⁾. A subgroup analysis also indicated that screening was particularly effective in men aged 55 to 69 years. These findings support the hypothesis that early detection through PSA testing may meaningfully reduce disease-related mortality in targeted populations

Greater Access to Curative Treatment Options

Early-stage prostate cancer (typically T1–T2 and localized disease) offers a wider range of definitive curative treatments, including radical prostatectomy, external beam radiation therapy, and active surveillance for low-risk tumors. Early identification through PSA screening increases the likelihood that men will be eligible for less invasive treatments, with a better prognosis and reduced cancer-related morbidity⁽¹¹⁾. Studies have shown that the 10-year prostate cancer-specific survival rate exceeds 90% for patients diagnosed at an early stage, underscoring the value of early detection⁽¹²⁾.

Enhanced Men's Health Awareness and Engagement

Although PSA testing is primarily aimed at prostate cancer detection, it often prompts broader engagement with healthcare systems, leading to the identification of other urologic or systemic health conditions. Men who undergo PSA screening are more likely to receive digital rectal examinations, urinary function evaluations, and counseling for sexual health and lifestyle modification⁽³⁾. This “spillover” effect enhances health literacy and promotes preventative care practices, particularly in middle-aged and older men who are otherwise under-screened for chronic diseases.

Potential for Risk Stratification and Individualized Surveillance

Modern approaches to PSA screening are increasingly refined through risk calculators and predictive tools that incorporate PSA kinetics, age, family history, ethnicity, and additional biomarkers such as prostate health index (PHI)⁽¹³⁾ or 4Kscore⁽¹³⁾. These tools enable more precise risk stratification, reducing unnecessary biopsies while still identifying aggressive tumors⁽¹⁰⁾. The development of MRI-based strategies as a triage test after elevated PSA has further improved diagnostic precision and reduced overdiagnosis⁽¹³⁾.

Risks and Controversies: Contra Arguments

Overdiagnosis and Overtreatment

One of the most significant concerns surrounding PSA-based screening is overdiagnosis, defined as the detection of prostate cancers that would not have become clinically significant during a man's lifetime. It is estimated that between 20% and 50% of prostate cancers detected via PSA screening are indolent and unlikely to cause symptoms or mortality⁽¹⁴⁾. Overdiagnosis often leads to overtreatment, where

men undergo radical therapies such as prostatectomy or radiotherapy despite having low-risk tumors. These interventions are associated with substantial side effects including erectile dysfunction, urinary incontinence, and bowel complications that can severely impact quality of life^(5,15).

Even with the increasing popularity of active surveillance for low-risk prostate cancer, data suggest that many men and clinicians remain uncomfortable with non-interventional approaches, resulting in unnecessary definitive treatment⁽¹⁶⁾. The psychological burden of living with an untreated cancer, even if indolent, may also drive patients toward more aggressive management.

Lack of Consistent Mortality Benefit

While European trials (e.g., ERSPC)^(6,17) support a reduction in prostate cancer-specific mortality, other large-scale studies⁽⁶⁾ have failed to replicate these findings. Notably, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which randomized over 76,000 men in the U.S., reported no statistically significant difference in prostate cancer mortality between the screening and usual care groups after 13 years of follow-up⁽¹⁷⁾. However, the validity of this finding has been questioned due to high rates of PSA testing in the control arm (contamination), which likely diluted the difference between the groups⁽¹⁸⁾.

This inconsistency in outcomes has fueled debates about the true efficacy of population-wide PSA screening and led to divergent recommendations across guideline bodies. Critics argue that the modest mortality benefit may not justify the widespread harms caused by overdiagnosis and treatment.

Psychological Harm and False-Positive Results

PSA screening is associated with a relatively high rate of false-positive results, primarily due to its low specificity. Approximately 70%–75% of men with elevated PSA levels (>4.0 ng/mL) who undergo prostate biopsy are found not to have cancer. These false alarms can lead to considerable psychological distress, repeated testing, unnecessary invasive procedures, and long-term anxiety about cancer risk^(3,19).

Moreover, prostate biopsy itself is not without risk—it can result in bleeding, infection, and hospitalization, especially when performed repeatedly⁽¹⁹⁾. The emotional toll on men subjected to these false-positive scenarios is increasingly recognized in the literature and contributes to the broader concerns over the harms of indiscriminate PSA-based screening programs.

Health System Burden and Cost-Effectiveness Concerns

PSA-based screening, when implemented at a population level, can significantly strain healthcare systems due to the high volume of follow-up

diagnostics, such as repeat PSA tests, digital rectal examinations, prostate biopsies, MRI scans, and pathology reviews^(20,21). Each elevated PSA result necessitates further clinical investigation—often leading to procedures that are expensive, resource-intensive, and not always clinically warranted⁽²⁰⁾. In settings with limited healthcare resources, this can divert funding and personnel from other essential health services⁽²⁰⁾.

The cost-effectiveness of PSA screening may be considered cost-effective in high-income settings with structured follow-up and risk stratification protocols, it is far less efficient in systems with unregulated screening practices or low adherence to active surveillance⁽²¹⁾. Moreover, overtreatment of low-risk prostate cancer contributes to unnecessary expenditures on surgeries, radiotherapy, and long-term management of treatment-related complications⁽²²⁾. These cost implications have led many health policy experts to advocate for targeted or risk-adapted screening strategies, rather than universal screening. In low- and middle-income countries, indiscriminate PSA screening may be unsustainable and potentially inequitable, widening the gap in healthcare access and outcomes between socioeconomic groups.

International Guidelines and Recommendations

The use of PSA screening for prostate cancer has led to divergent policies among international professional bodies due to variations in study interpretations, healthcare system capacities, and population risk profiles. Recent guidelines emphasize a shift from mass screening toward individualized, risk-adapted strategies, taking into account age, life expectancy, comorbidities, and patient preferences.

United States Preventive Services Task Force (USPSTF)⁽⁷⁾

The USPSTF's 2018 update marked a key turning point in PSA screening policy. The task force gave a Grade C recommendation for men aged 55 to 69 years, meaning that the decision to undergo PSA-based screening should be an individualized choice, made through shared decision-making with the patient after discussion of potential benefits and harms⁽⁷⁾. For men aged 70 years or older, the USPSTF recommends against PSA screening, citing a greater risk of overdiagnosis and overtreatment, and a lower probability of net benefit due to reduced life expectancy and increased competing health risks.

European Association of Urology (EAU)^(4,13)

The EAU 2024 guidelines advocate for risk-adapted, evidence-based screening. Rather than mass screening, EAU supports a baseline PSA test at age 45–50 to determine long-term risk and guide future screening intervals⁽⁴⁾. The EAU encourages the use of additional tools such as PSA density, PSA velocity, and advanced molecular biomarkers (e.g., PHI, 4Kscore) to improve specificity. Importantly, the EAU also recommends multiparametric MRI (mpMRI) prior to prostate biopsy in men with elevated PSA, a

practice that has been shown to reduce unnecessary biopsies and improve detection of clinically significant cancers⁽¹³⁾.

National Comprehensive Cancer Network (NCCN) – United States⁽⁷⁾⁽¹⁰⁾

The NCCN guidelines provide a more detailed risk-stratified approach, recommending:

- Baseline PSA testing at age 45 for men at average risk,
- Earlier and more frequent testing for high-risk groups (African-American men or those with a family history),
- Biopsy consideration at PSA ≥ 3.0 ng/mL or based on abnormal DRE,
- Use of MRI and secondary markers (PHI, 4Kscore) prior to biopsy in borderline cases

The NCCN also strongly supports active surveillance for low-risk and some favorable intermediate-risk prostate cancers, aiming to reduce overtreatment while maintaining oncologic safety.

Canadian Task Force on Preventive Health Care (CTFPHC)⁽³⁾⁽⁷⁾

In contrast, Canadian guidelines are more conservative. The CTFPHC (2014) recommends against PSA-based screening in asymptomatic men of all age groups, citing uncertainty in mortality benefit and a high probability of harm from overdiagnosis and overtreatment. However, these recommendations have been criticized for not incorporating newer evidence on MRI-based triage and risk stratification.

United Kingdom – National Health Service (NHS) and NICE⁽⁴⁾⁽¹³⁾

In the UK, the Prostate Cancer Risk Management Programme (PCRMP) does not recommend organized screening but allows opportunistic PSA testing in men aged 50 and over, provided they receive thorough counseling about the test’s limitations. The NICE guidelines similarly recommend against systematic screening but support PSA testing for symptomatic men or those requesting it after informed discussion⁽¹³⁾.

World Health Organization (WHO)⁽⁴⁾⁽⁷⁾

The WHO does not currently recommend population-based PSA screening for prostate cancer in any region due to concerns about feasibility, cost-effectiveness, and potential harms in lower-resource settings. Instead, the WHO advocates for contextualized decision-making, especially in countries with limited access to follow-up diagnostics and urologic care⁽⁷⁾.

Risk-Stratified and Individualized Approach

Given the complex balance between the potential benefits and harms of PSA screening, a one-size-fits-all approach is no longer considered appropriate. Instead, personalized screening

strategies are increasingly promoted by leading urological and oncological societies.

Table 1. Clinical Summary : Screening for Prostate Cancer⁽⁷⁾

Organis ation	Age Group	Recomme ndations	Notes
USPSTF (USA) ⁽⁷⁾	55–69	Shared decision-making	Does not support mass screenin g
EAU (Europe) ⁽⁴⁾⁽¹³⁾	45+	Risk-adapted, baseline PSA, mpMRI before biopsy	Supports biomark ers and imaging
NCCN (USA) ⁽⁷⁾	45+	Risk-stratified screening	Includes MRI, molecu lar markers
CTFPHC (Canada) ⁽⁷⁾	All	Recomme nds against screening	Concern ed about overdiag nosis
NICE/N HS (UK) ⁽⁷⁾	50+	Informed patient-initiated screening	Not a populati on-wide program
WHO ⁽⁷⁾	Global	Does not support mass screening	Recom mends individu alized approac hes

Stratifying Based on Age, Risk, and Comorbidity

Age remains a major determinant of prostate cancer risk and screening benefit. Men aged 55–69 benefit the most from screening in terms of mortality reduction, while men over 70 are more likely to suffer from competing mortality risks and treatment harms⁽³⁾. Family history of prostate cancer especially in first-degree relatives and African ancestry are associated with significantly increased lifetime risk and justify earlier and more frequent screening^(2,23)

Biomarkers and PSA Derivatives

To improve diagnostic performance, several PSA-related parameters are now used to enhance

specificity⁽²⁾:

- PSA density (PSAD): PSA adjusted for prostate volume; values >0.15 ng/mL/cm³ suggest increased cancer risk.
- PSA velocity (PSAV): Rate of PSA increases over time; rapid rises may indicate aggressive disease.
- Free-to-total PSA ratio (f/tPSA): Lower ratios (<10 – 15%) are associated with a higher probability of cancer.

Advanced biomarkers, such as Prostate Health Index (PHI), 4Kscore, and SelectMDx, provide molecular risk estimates to guide biopsy decisions and reduce unnecessary procedures.

Integration of Multiparametric MRI

Multiparametric MRI (mpMRI) has become a cornerstone in the individualized screening paradigm⁽⁶⁾. When used after elevated PSA but prior to biopsy, mpMRI significantly improves the detection of clinically significant cancer and reduces detection of low-risk, indolent tumors.⁵ This approach aligns with contemporary strategies that seek to minimize overtreatment while ensuring timely diagnosis of aggressive disease.

CONCLUSION

Prostate-specific antigen (PSA) screening represents one of the most widely studied and debated strategies in cancer prevention. While it has demonstrated a clear potential to reduce prostate cancer-specific mortality—particularly in men aged 55–69 years—its population-wide implementation remains contentious due to the inherent limitations of PSA as a biomarker and the substantial risk of overdiagnosis.^(7,14) Indolent tumors that would not have caused clinical harm are frequently detected, often resulting in overtreatment and long-term adverse effects on urinary, sexual, and psychological health.⁽¹⁴⁾

The evidence from large-scale trials, such as ERSPC^(ref asli) and PLCO^(ref asli), offers conflicting outcomes, reflecting variations in trial design, adherence to protocols, and control group contamination. This ambiguity has prompted major guideline bodies to shift away from universal screening models in favor of personalized, risk-adapted screening strategies that incorporate age, family history, ethnicity, comorbidities, and life expectancy. Technological advancements, including the use of multiparametric MRI and molecular biomarkers (e.g., PHI, 4Kscore), offer improved risk stratification and have contributed to more precise diagnostic pathways⁽¹³⁾. These tools help reduce unnecessary biopsies and minimize harm, aligning with the principles of value-based care and precision medicine.

Given these complexities, the most ethically sound and clinically effective approach is to adopt a shared decision-making model, wherein patients are fully informed of the benefits and harms of PSA

screening. This model respects individual values and preferences, while empowering clinicians to tailor recommendations based on up-to-date, evidence-based risk assessments. Ultimately, the goal of PSA screening should not be merely early detection, but rather selective identification of clinically significant cancers, with a focus on balancing longevity with quality of life. Continued research, including long-term follow-up studies and economic evaluations, will be essential to refine screening protocols and optimize outcomes for diverse populations.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209–49.
2. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: Facts, statistics, and interpretation in response to the US Preventive Services Task Force review. *J Clin Oncol*. 2012;30(21):2581–4.
3. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. *Jama*. 2014;311(11):1143–9.
4. Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darragh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*. 2024;86(2):148–63.
5. Wilt TJ, Scardino PT, Carlsson S V., Basch E. Prostate-Specific Antigen Screening in Prostate Cancer: Perspectives on the Evidence. *J Natl Cancer Inst*. 2014;106(3):dju010.
6. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. *N Engl J Med*. 2009;360(13):1320–8.
7. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018;319(18):1901–13.
8. Lilja H, Ulmert D, Vickers A. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. *Nat Rev Cancer*. 2008;8(4):268–278.
9. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower. *JAMA*. 2005;291(1):66–70.
10. Loeb S. Evidence-based versus personalized prostate cancer screening: Using baseline prostate-specific antigen measurements to individualize screening. *J Clin Oncol*. 2016;34(23):2684–6.

11. Guo Y, Dong X, Mao S, Yang F, Wang R, Ma W, et al. Causes of Death after Prostate Cancer Diagnosis: A Population-Based Study. *Oxid Med Cell Longev*. 2022;2022(1):1–12.
12. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. *N Engl J Med*. 2016;375(15):1415–24.
13. Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. *N Engl J Med*. 2021;385(10):908–20.
14. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. *J Natl Cancer Inst*. 2021;101(6):374–383.
15. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *N Engl J Med*. 2016;375(15):1425–37.
16. Loeb S, Bruinsma S, Nicholson J, Briganti A, Pickles T, Kakehi Y, et al. Active surveillance for prostate cancer: A systematic review of clinico-pathologic variables and biomarkers for risk stratification. *Eur Urol*. 2015;67(4):619–26.
17. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. *J Natl Cancer Inst*. 2012;104(2):125–132.
18. Pinsky PF, Prorok PC, Kramer BS. Prostate Cancer Screening — A Perspective on the Current State of the Evidence. *N Engl J Med*. 2017;376(13):1285–9.
19. Volk RJ, Spann SJ, Cass AR, Hawley ST. Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. *Ann Fam Med*. 2003;1(1):22–8.
20. Heijnsdijk EAM, Carvalho TM de, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data. *J Natl Cancer Inst*. 2015;107(1):dju366.
21. Shteynshlyuger A, Andriole GL. Cost-Effectiveness of Prostate Specific Antigen Screening in the United States: Extrapolating From the European Study of Screening for Prostate Cancer. *J Urol*. 2011;185(3):828–32.
22. Klotz L. Prostate cancer overdiagnosis and overtreatment. *Curr Opin Endocrinol Diabetes Obes*. 2013;20(3):204–9.
23. Lillard JW, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate

cancer: A literature review. *Cancer*. 2022;128(21):3787–95.



This work is licensed under
a Creative Commons Attribution

